Forget Ozempic: This Obesity‑Drug Giant Is Grabbing the Biggest Slice of the GLP‑1 Gold Rush
Key Points
Ozempic is a well-recognized name in the weight loss drug space.
The product was the first GLP-1 drug to enter the market after gaining approval in 2017.
Everyone has been talking about Ozempic in recent years. You may have seen the name in the news or even know someone who is taking this blockbuster drug. Though Ozempic, made by Novo Nordisk, is approved for type 2 diabetes, the drug has also been prescribed for weight loss. It's part of the popular GLP-1 class of drugs.
Novo was first to market with a GLP-1 drug in 2017 and maintained leadership for a while. But that has changed over the past year, as another player roared into the top spot. So, as an investor, if you're looking for a GLP-1 winner, you may want to forget Ozempic. The following obesity-drug giant is grabbing the biggest slice of this gold rush.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks »
Image source: Getty Images.
How do GLP-1 drugs work?
First, a quick note on GLP-1 drugs. These products work by interacting with hormonal pathways involved in digestion, and by doing this, they help regulate a person's blood sugar levels -- and control appetite. As a result, they've helped those suffering from diabetes and aiming to lose weight. Regulators have approved Novo's semaglutide for type 2 diabetes as Ozempic and for obesity as Wegovy.
Now, let's consider the weight loss powerhouse that's surged ahead of Novo. The company I'm talking about is Eli Lilly (NYSE: LLY). Lilly makes tirzepatide, marketed as Mounjaro for type 2 diabetes and as Zepbound for weight loss. These drugs entered the market later than Novo's, but they've taken the lead.
In the U.S., Lilly took leadership a year ago and has progressively increased its market share. Lilly now holds 60% of the market, while Novo's share has fallen to 39%.
Lilly reported triple-digit revenue growth for Mounjaro and for Zepbound in the recent quarter, and together these drugs brought in more than $11 billion in revenue.
Why is this company a leader?
Why has Lilly jumped ahead? The company has done a great job of ramping up its manufacturing, making doses of its product readily available for patients. This is key because both semaglutide and tirzepatide were in shortage a couple of years ago.
Most importantly, Lilly ran a head-to-head study of Zepbound versus Wegovy, and it showed that the Lilly drug helped people lose more weight. This may have prompted more patients and doctors to opt for the Lilly product.
Though Novo recently launched a Wegovy pill -- the other commercialized GLP-1s are injectables -- Lilly could be set for a win in this space too. The company's oral weight loss candidate is under regulatory review right now, and unlike the Wegovy pill, it doesn't involve dietary restrictions. So it's more of a hassle-free option for patients.
All of this suggests that Lilly could continue grabbing share of this gold rush, making it a great buy for long-term investors.
Should you buy stock in Eli Lilly right now?
Before you buy stock in Eli Lilly, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $415,256!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,133,904!*
Now, it’s worth noting Stock Advisor’s total average return is 889% — a market-crushing outperformance compared to 193% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of February 19, 2026.
Adria Cimino has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.
Related Articles
New Fed Chair Warsh Takes Office: Major Shift in Monetary Policy? US Dollar Short-Term Rebound, 2026 Investment Strategy Analysis
TradingKey - At the start of 2026, global financial markets witnessed a major leadership change as U.S. President Trump officially nominated Kevin Warsh as the next Federal Reserve Chair. Pending Senate confirmation, he will succeed Jerome Powell this May to lead the world’s most influential central bank.
Should You Buy Berkshire Hathaway Post-Warren Buffett? What's Warren Buffett's Advice for 2026 Investment?
Berkshire built up a hoard of cash through 2025, accumulating nearly $400 billion—more than it had ever held before. That was by design. Berkshire, instead of joining the artificial intelligence rally that led the headlines, put the cash into short-term U.S. Treasuries with about 3.6% yields.
Digital Asset Rotation: Navigating Market Volatility With the Best Cheap Cryptos for 2026
Navigate the 2026 crypto rotation: Analyze the best cheap cryptos like Solana, Chainlink, and XRP amid Bitcoin’s volatility. Discover top picks for utility and long-term gains.
